News
Language
Live Cam
Contact
Imprint
Ulm
English
en
Français
fr
Deutsch
de
News
Language
Live Cam
Contact
Imprint
English
en
Français
fr
Deutsch
de
EKM WS18 Introduction to Clinical Medicine
GTE Historical development of medicine
Medicine
Button
Robert Koch Institute
Red List
Pub Med
Dolosys
Cardiology
JUL
28
Mitochondrial uncoupling therapy reduces established atherosclerosis in mice
By:
Irene Fernández-Ruiz
on
JUL
28
Nature Reviews Cardiology, Published online: 28 July 2026; doi:10.1038/s41569-026-01330-7Targeting systemic metabolism through mild mitochondrial uncoupling with a controlled-release mitochondrial protonophore can reduce atherosclerosis in a mouse model of cardiometabolic syndrome, even when administered at late stages of disease progression.
Read more >>
JUL
27
Cardioprotective properties of empagliflozin and other SGLT2 inhibitors
By:
Thomas A. Zelniker
on
JUL
27
Nature Reviews Cardiology, Published online: 27 July 2026; doi:10.1038/s41569-026-01325-4In this Review, Zelniker and Braunwald summarize the cardioprotective effects of empagliflozin and other sodium–glucose cotransporter 2 inhibitors and discuss the underlying mechanisms of these effects, including haemodynamic modulation, improved mitochondrial bioenergetics and activation of cytoprotective pathways that inhibit oxidative stress, inflammation and fibrosis.
Read more >>
JUL
23
The cardiac 4D nucleome: nuclear and chromatin dynamics across development, disease and ageing
By:
Yinuo Wang
on
JUL
23
Nature Reviews Cardiology, Published online: 23 July 2026; doi:10.1038/s41569-026-01322-7In this Review, Wang and Dobreva discuss nuclear and chromatin organization and remodelling during cardiac development, disease and ageing, highlight emerging methods to investigate nuclear architecture, describe how mechanical and metabolic signals shape the cardiac 4D nucleome, and examine the therapeutic and translational implications for cardiovascular health and disease.
Read more >>
JUL
17
The renaissance of cardiac glycosides in heart failure: why, for whom and when
By:
Antonio Cannata
on
JUL
17
Nature Reviews Cardiology, Published online: 17 July 2026; doi:10.1038/s41569-026-01323-6Cardiac glycosides were the cornerstone of heart failure treatment for decades, but their use progressively declined after the introduction of modern prognostic medications. Two clinical trials now report that cardiac glycosides can reduce the risk of worsening heart failure events in patients with heart failure with reduced ejection fraction. These results do not mandate a paradigm shift but support a specific role for cardiac glycosides in selected patients.
Read more >>
JUL
16
YAP at the heart of cardiac regeneration
By:
Ghulam Mehdi Dar
on
JUL
16
Nature Reviews Cardiology, Published online: 16 July 2026; doi:10.1038/s41569-026-01328-1In this Journal Club article, Dar describes the first study to report the transcriptional coactivator YAP as a central regulator of cardiac regeneration in mice.
Read more >>
JUL
14
In the era of AI, omics and organoids, animal models are still needed in cardiovascular research
By:
Petra Kleinbongard
on
JUL
14
Nature Reviews Cardiology, Published online: 14 July 2026; doi:10.1038/s41569-026-01327-2As artificial intelligence (AI), multiomics and human organoids reshape cardiovascular research, calls to replace animal models are accelerating. We argue that understanding complex, multiorgan cardiovascular disease requires an integrated framework in which in vivo, in vitro and computational models each provide complementary biological insights.
Read more >>
JUL
13
World Heart Federation Roadmap on cardiac rehabilitation: a pathway to lifelong cardiovascular health
By:
Julie Redfern
on
JUL
13
Nature Reviews Cardiology, Published online: 13 July 2026; doi:10.1038/s41569-026-01312-9In this Roadmap from the World Heart Federation, cardiac rehabilitation is reframed as programmes to promote lifelong cardiovascular health. Redfern et al. identify roadblocks and propose multifaceted solutions, together with international case studies of successful implementation.
Read more >>
JUL
08
Transfer of a gain-of-function
PCSK9
gene to induce atherosclerosis in mice
By:
Julián Albarrán-Juárez
on
JUL
08
Nature Reviews Cardiology, Published online: 08 July 2026; doi:10.1038/s41569-026-01326-3In this Tools of the Trade article, Albarrán-Juárez describes the utility of the adeno-associated virus-PCSK9 model of atherosclerosis.
Read more >>
Weitere Beiträge
Clinical Oncology
JUL
31
More options, more questions in the management of early relapsed and/or refractory multiple myeloma
By:
Carlyn Rose Tan
on
JUL
31
Nature Reviews Clinical Oncology, Published online: 31 July 2026; doi:10.1038/s41571-026-01191-6In MonumenTAL-3, the G-protein-coupled receptor class C group 5 memberD-directed bispecific T cell engager talquetamab combined with either daratumumab or daratumumab–pomalidomide conferred significantly longer progression-free survival than daratumumab–pomalidomide–dexamethasone in patients with relapsed and/or refractory multiple myeloma (≥1 prior line of therapy). These results herald a new therapeutic option for such patients but also raise questions regarding how talquetamab-based regimens should be integrated with B cell maturation antigen-directed T cell-redirecting therapies.
Read more >>
JUL
30
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
By:
Solange Peters
on
JUL
30
Nature Reviews Clinical Oncology, Published online: 30 July 2026; doi:10.1038/s41571-026-01188-1With the expanded use of antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) in combination, clinicians increasingly face overlapping toxicity profiles with uncertain attribution. The authors of this Review propose a framework that links three interacting layers: immune activation, payload cytotoxicity and payload-independent effects, and provide practical algorithms for evaluation, initial management and treatment resumption in patients receiving ADC monotherapy or ICI–ADC combinations.
Read more >>
JUL
29
De-escalation trials in multiple myeloma: past, present and future
By:
Hira Mian
on
JUL
29
Nature Reviews Clinical Oncology, Published online: 29 July 2026; doi:10.1038/s41571-026-01186-3Current treatment approaches for patients with multiple myeloma are characterized by a ‘more is better’ philosophy aiming for deep and long-term clinical responses. The authors of this Review challenge this paradigm, presenting several de-escalation strategies that do not compromise long-term efficacy and proposing a framework for the design of trials testing further de-escalation approaches.
Read more >>
JUL
28
Electronic cigarettes, smoking and lung cancer risk: some evidence about the continuum of harm
By:
Peter G. Shields
on
JUL
28
Nature Reviews Clinical Oncology, Published online: 28 July 2026; doi:10.1038/s41571-026-01192-5Since the introduction of vaping with electronic cigarettes in the late 2000s, controversy has continued to exist regarding the risks and benefits. Many studies indicate that electronic cigarettes are an effective smoking-cessation tool. Now, a large database analysis by Kim et al. provides a glimpse of the risks of lung cancer for smokers who quit with versus without vaping.
Read more >>
JUL
24
Towards liquid biopsy-based analysis of antitumour immunity
By:
Klaus Pantel
on
JUL
24
Nature Reviews Clinical Oncology, Published online: 24 July 2026; doi:10.1038/s41571-026-01181-8Advances in multimodal analyses of diverse cell types and cellular products present in the blood have presented opportunities to non-invasively and repeatedly assess systemic immune dynamics, predict and monitor responses to immunotherapies, and detect emerging resistance in patients with cancer. In this Review, the authors discuss various insights on systemic antitumour immune responses that can be gleaned through such liquid biopsy-based analysis of circulating tumour-derived biomarkers and/or immune cells and their implications for immunotherapy.
Read more >>
JUL
20
Does OptiTROP-Lung05 open a new frontier for first-line ADC–ICI combinations in NSCLC?
By:
Myung-Ju Ahn
on
JUL
20
Nature Reviews Clinical Oncology, Published online: 20 July 2026; doi:10.1038/s41571-026-01183-6Interim data from the phase III OptiTROP-Lung05 trial demonstrate that adding the TROP2-targeted antibody–drug conjugate sacituzumab tirumotecan to pembrolizumab improves progression-free survival in patients with PD-L1-positive advanced-stage non-small-cell lung cancer. Herein, I present several questions that need to be addressed before this combination can be considered a new standard of care, such as effect on overall survival, long-term safety, global generalizability and biomarker refinement.
Read more >>
JUL
16
Second-line
177
Lu-edotreotide shows promise in GEP NETs
By:
Diana Romero
on
JUL
16
Nature Reviews Clinical Oncology, Published online: 16 July 2026; doi:10.1038/s41571-026-01187-2Second-line 177Lu-edotreotide shows promise in GEP NETs
Read more >>
JUL
16
Crossover does not confound, it informs:
177
lutetium-PSMA-617 as an example
By:
Martin W. Schoen
on
JUL
16
Nature Reviews Clinical Oncology, Published online: 16 July 2026; doi:10.1038/s41571-026-01182-7Crossover in trials should not be viewed as confounding, but as informative. Crossover reveals whether deferring therapy produces outcomes comparable to those from earlier use. Statistical crossover-adjustment methods carry unaccounted biases and limited clinical utility. Crossover should instead guide treatment-sequencing decisions, weighing toxicity and cost against any overall survival benefit from earlier intervention.
Read more >>
Weitere Beiträge
Endocrinology
JUL
30
Paracrine signalling in thermogenesis
By:
Claire Greenhill
on
JUL
30
Nature Reviews Endocrinology, Published online: 30 July 2026; doi:10.1038/s41574-026-01292-3Paracrine signalling in thermogenesis
Read more >>
JUL
30
Links between bone fractures and the gut microbiota
By:
Claes Ohlsson
on
JUL
30
Nature Reviews Endocrinology, Published online: 30 July 2026; doi:10.1038/s41574-026-01286-1In this Review, the authors describe evidence linking the gut microbiota to bone fractures. They discuss findings from rodent models and human studies on the effects of the gut microbiota on bone and muscle and explore the mechanisms through which the gut microbiota is associated with bone fractures.
Read more >>
JUL
30
Therapeutic potential of targeting the orexin (hypocretin) system in sleep disorders
By:
Birgitte R. Kornum
on
JUL
30
Nature Reviews Endocrinology, Published online: 30 July 2026; doi:10.1038/s41574-026-01277-2Understanding the key mechanisms underlying sleep and wake states is essential for developing effective treatments for sleep disorders. Here, the authors discuss how the orexin (also known as hypocretin) system — a central regulator of sleep and wakefulness — is a key target in the development of treatments for sleep disorders.
Read more >>
JUL
28
Anti-IL-11 treatment improves ovarian function by reducing matrix stiffness
By:
Olivia Tysoe
on
JUL
28
Nature Reviews Endocrinology, Published online: 28 July 2026; doi:10.1038/s41574-026-01288-zAnti-IL-11 treatment improves ovarian function by reducing matrix stiffness
Read more >>
JUL
28
Local catecholamine catabolism blunts lipolysis in ageing adipose tissue
By:
Fadi Khalaf
on
JUL
28
Nature Reviews Endocrinology, Published online: 28 July 2026; doi:10.1038/s41574-026-01290-5Local catecholamine catabolism blunts lipolysis in ageing adipose tissue
Read more >>
JUL
27
Dose matters: haploinsufficiency in osteogenesis imperfecta
By:
Anastasia Sclocco
on
JUL
27
Nature Reviews Endocrinology, Published online: 27 July 2026; doi:10.1038/s41574-026-01282-5Osteogenesis imperfecta type 1 can be caused by haploinsufficient variants of COL1A1 and can be difficult to diagnose and manage. In this Review, the authors cover the role of collagen type I haploinsufficiency in osteogenesis imperfecta type 1’s pathogenesis, treatment strategies currently under investigation and aspects of this disease that require further research.
Read more >>
JUL
21
Diagnosis, staging and management of obesity: a synthesis of contemporary guidelines
By:
Clara E. Tandar
on
JUL
21
Nature Reviews Endocrinology, Published online: 21 July 2026; doi:10.1038/s41574-026-01279-0Obesity is a chronic, adiposity-based disease with multiple, competing definitions. In the past 2 years, major professional societies have advanced new diagnostic frameworks that incorporate multimodal assessment of adiposity and its clinical consequences. In this Review, Tandar et al. evaluate contemporary anthropometric and body composition measurements, synthesize new frameworks and guidelines for the diagnosis and staging of obesity, and discuss their implications for clinical practice.
Read more >>
JUL
17
Nutrient and non-nutrient regulators of insulin secretion
By:
Jelena Kolic
on
JUL
17
Nature Reviews Endocrinology, Published online: 17 July 2026; doi:10.1038/s41574-026-01281-6This Review explores the regulation of insulin secretion, including the effects of various nutrient and non-nutrient factors. An improved understanding of the complexities of how insulin secretion is regulated could lead to targeted treatments in the future.
Read more >>
Weitere Beiträge
GI and Hepatology
JUL
31
Mechanisms, management and prevention of anorectal sexually transmitted infections
By:
Phyu Mon Latt
on
JUL
31
Nature Reviews Gastroenterology & Hepatology, Published online: 31 July 2026; doi:10.1038/s41575-026-01232-6Anorectal bacterial sexually transmitted infections (STIs) remain a global health challenge. This Review provides an overview of anorectal bacterial STIs focusing on chlamydia, gonorrhoea and syphilis, with insights into global burden, pathophysiology, management and prevention, as well as highlighting knowledge gaps and research priorities.
Read more >>
JUL
29
Desynchronization of intestinal circadian clocks and gastrointestinal dysfunction
By:
Yuuki Obata
on
JUL
29
Nature Reviews Gastroenterology & Hepatology, Published online: 29 July 2026; doi:10.1038/s41575-026-01241-5Intestinal circadian clocks are emerging as important regulators of gastrointestinal physiology and homeostasis. Recent advances suggest that desynchronization of circadian clocks in distinct intestinal cell types could contribute to gastrointestinal dysfunction, highlighting new opportunities to understand disease mechanisms and identify future research priorities.
Read more >>
JUL
20
Understanding intrapancreatic fat: charting a path forward
By:
Erica Park
on
JUL
20
Nature Reviews Gastroenterology & Hepatology, Published online: 20 July 2026; doi:10.1038/s41575-026-01234-4Two independent Delphi-driven consensus initiatives have established the first standardized frameworks for defining, measuring and managing intrapancreatic fat. Their areas of agreement provide a foundation for clinical recognition, while key divergences in terminology, thresholds and evidence appraisal highlight critical questions that must be resolved through rigorous collaborative research.
Read more >>
JUL
17
Dupilumab shows promise in eosinophilic gastritis
By:
Eleni Kotsiliti
on
JUL
17
Nature Reviews Gastroenterology & Hepatology, Published online: 17 July 2026; doi:10.1038/s41575-026-01239-zDupilumab shows promise in eosinophilic gastritis
Read more >>
JUL
17
Precision adherence support for hepatitis C treatment
By:
Eleni Kotsiliti
on
JUL
17
Nature Reviews Gastroenterology & Hepatology, Published online: 17 July 2026; doi:10.1038/s41575-026-01238-0Precision adherence support for hepatitis C treatment
Read more >>
JUL
16
PIEZO1 senses the mechanics of liver regeneration
By:
Eleni Kotsiliti
on
JUL
16
Nature Reviews Gastroenterology & Hepatology, Published online: 16 July 2026; doi:10.1038/s41575-026-01237-1PIEZO1 senses the mechanics of liver regeneration
Read more >>
JUL
16
Steatosis fuels replacement liver metastases in colorectal cancer
By:
Eleni Kotsiliti
on
JUL
16
Nature Reviews Gastroenterology & Hepatology, Published online: 16 July 2026; doi:10.1038/s41575-026-01236-2Steatosis fuels replacement liver metastases in colorectal cancer
Read more >>
JUL
16
Conceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus
By:
Maxim S. Petrov
on
JUL
16
Nature Reviews Gastroenterology & Hepatology, Published online: 16 July 2026; doi:10.1038/s41575-026-01224-6In this Consensus Statement, a global multidisciplinary group of experts provide a structured framework and clear guidance on intrapancreatic fat deposition and fatty pancreas disorder.
Read more >>
Weitere Beiträge
Nephrology
JUL
30
Adressing the high burden of kidney disease: lessons from Taiwan
By:
I-Wen Wu
on
JUL
30
Nature Reviews Nephrology, Published online: 30 July 2026; doi:10.1038/s41581-026-01112-xTaiwan carries one of the world’s heaviest kidney disease burdens globally; however, its single-payer universal health-care system has enabled policy-driven transformation of kidney care through population-level screening, multidisciplinary pay-for-performance programmes, data-driven surveillance and digital innovation. These strategies have reduced disease incidence and improved outcomes, and provide a replicable model for health systems elsewhere.
Read more >>
JUL
28
Nephrology care for incarcerated people: a call to action
By:
Laura J. Maursetter
on
JUL
28
Nature Reviews Nephrology, Published online: 28 July 2026; doi:10.1038/s41581-026-01108-7The carceral system has the impossible task of providing appropriate care for a vulnerable population while limiting taxpayer spending. Although many risk factors for incarceration also increase the risk of chronic kidney disease (CKD), specific CKD screening requirements or treatment accountability are lacking, which compromises patient care.
Read more >>
JUL
28
Insights from integrative spatial transcriptomics in sepsis-associated acute kidney injury
By:
Moritz Uhlig
on
JUL
28
Nature Reviews Nephrology, Published online: 28 July 2026; doi:10.1038/s41581-026-01107-8The complexity of the host responses that underlie sepsis-associated acute kidney injury (SA-AKI) complicates patient management and contributes to its high mortality. Here, the authors examine insights into the pathophysiology of SA-AKI gained from the integration of high-resolution spatial transcriptomics with other multi-omics approaches, and consider how these technologies might enable targeted therapeutic interventions.
Read more >>
JUL
28
Epigenetic regulation of kidney development
By:
Samir S. El-Dahr
on
JUL
28
Nature Reviews Nephrology, Published online: 28 July 2026; doi:10.1038/s41581-026-01105-wThis Review describes current understanding of the epigenetic regulation of kidney development. It describes the epigenetic drivers of cell fate decisions made by nephron progenitor cells, the chromatin landscape of accessible regulatory elements that orchestrate these decisions, and the functional consequences for congenital kidney diseases and the programming of adult kidney disease.
Read more >>
JUL
27
WNT organizers control nephron patterning in organoids
By:
Susan J. Allison
on
JUL
27
Nature Reviews Nephrology, Published online: 27 July 2026; doi:10.1038/s41581-026-01113-wWNT organizers control nephron patterning in organoids
Read more >>
JUL
27
The first-in-human combined bladder and kidney transplant
By:
Ellen F. Carney
on
JUL
27
Nature Reviews Nephrology, Published online: 27 July 2026; doi:10.1038/s41581-026-01114-9The first-in-human combined bladder and kidney transplant
Read more >>
JUL
24
Beyond paediatric nephrology: gaps in care for young adults
By:
Michael Rauchman
on
JUL
24
Nature Reviews Nephrology, Published online: 24 July 2026; doi:10.1038/s41581-026-01110-zThe prevalence of kidney disease is increasing in children and young adults, who face a lifetime of chronic disease with considerable morbidity and mortality. However, a critical shortage in the paediatric nephrology workforce and deficiencies in paediatric-to-adult transition care mean that we fail to meet the needs of this vulnerable population. Paediatric and adult nephrologists need to take collaborative action to address this crisis.
Read more >>
JUL
23
Disease modification in lupus nephritis: towards a pathophysiology-based treatment paradigm
By:
Mieke van Schaik
on
JUL
23
Nature Reviews Nephrology, Published online: 23 July 2026; doi:10.1038/s41581-026-01103-yThis Review provides an overview of the pathophysiology of systemic lupus erythematosus as well as drugs that have been developed to target these pathophysiological processes. The authors also synthesize a translational approach aimed at enabling disease modification in lupus nephritis through the integration of glucocorticoids and conventional antiproliferative agents with immunomodulatory drugs.
Read more >>
Weitere Beiträge
Neurology
Rheumatology
JUL
31
Controlled release of magnesium ions shapes osteoporotic bone repair
By:
Sarah Onuora
on
JUL
31
Nature Reviews Rheumatology, Published online: 31 July 2026; doi:10.1038/s41584-026-01418-xAn osteoimmunomodulatory implant that enables finely tuned release of magnesium ions could offer a way to enhance osteoporotic bone repair.
Read more >>
JUL
31
From psoriatic plaque to synovium: decoding the skin–joint axis in psoriatic arthritis
By:
Maria Gabriella Raimondo
on
JUL
31
Nature Reviews Rheumatology, Published online: 31 July 2026; doi:10.1038/s41584-026-01412-3This Review synthesizes evidence for a skin–joint axis in psoriatic arthritis (PsA), highlighting key mechanisms that might drive the transition from psoriasis to PsA. The authors emphasize that further research into this axis could be important for identifying biomarkers, informing patient stratification and predicting which patients will progress to PsA.
Read more >>
JUL
30
PD-1 agonism puts the brakes on pathogenic T cell responses in RA
By:
Holly Webster
on
JUL
30
Nature Reviews Rheumatology, Published online: 30 July 2026; doi:10.1038/s41584-026-01417-yPD-L2-mediated activation of PD-1 signalling in rheumatoid arthritis suppresses pro-inflammatory cytokine production and regulates pathogenic B cell responses.
Read more >>
JUL
28
AI detects signs of inflammatory arthritis in hand images
By:
Cinja Nadana Koller
on
JUL
28
Nature Reviews Rheumatology, Published online: 28 July 2026; doi:10.1038/s41584-026-01415-0Automatic assessment of joints by artificial intelligence (AI) or computer vision using photographs or videos can support the detection and/or monitoring of arthritis. Ideally, these data combined with other digital biomarkers, including patient-reported outcomes, can be implemented into clinical workflows for remote patient monitoring.
Read more >>
JUL
22
Hypoxia as an amplifier of synovial inflammation in rheumatoid arthritis
By:
Mary Canavan
on
JUL
22
Nature Reviews Rheumatology, Published online: 22 July 2026; doi:10.1038/s41584-026-01397-zIn rheumatoid arthritis (RA) a hypoxic gradient develops in the synovium, which shapes inflammation and immune responses. In this Review, the authors provide insights into the role of hypoxia in the pathogenesis of RA, discuss its role in the wider integrated signalling network that drives inflammation and highlight how hypoxia can be targeted therapeutically to treat RA.
Read more >>
JUL
16
Secukinumab shows diverging efficacy in PMR and GCA
By:
Jessica McHugh
on
JUL
16
Nature Reviews Rheumatology, Published online: 16 July 2026; doi:10.1038/s41584-026-01413-2In two phase III trials, secukinumab improved rates of sustained remission and reduced glucocorticoid use in polymyalgia rheumatica but did not improve outcomes in giant cell arteritis.
Read more >>
JUL
13
Lymph node ‘hideouts’ shield B cells from antibody therapy
By:
Jessica McHugh
on
JUL
13
Nature Reviews Rheumatology, Published online: 13 July 2026; doi:10.1038/s41584-026-01408-zLymph node architecture sequesters B cells away from effector cells, limiting antibody-mediated depletion and highlighting tissue remodelling as a strategy to improve therapeutic responses.
Read more >>
JUL
09
Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases
By:
Cem Gabay
on
JUL
09
Nature Reviews Rheumatology, Published online: 09 July 2026; doi:10.1038/s41584-026-01395-1This Review provides an update on the interleukin 1 (IL-1) family of cytokines in inflammatory and rheumatic diseases. The authors discuss advances in mechanistic understanding and highlight therapeutic developments in targeting this family of cytokines.
Read more >>
Weitere Beiträge
Urology
JUL
27
The urinary microbiome, overactive bladder and bladder pain syndrome/interstitial cystitis — mechanisms, diagnostics and therapeutic opportunities
By:
Martina Spazzapan
on
JUL
27
Nature Reviews Urology, Published online: 27 July 2026; doi:10.1038/s41585-026-01174-3This Review synthesizes current evidence on the urinary microbiome in overactive bladder and bladder pain syndrome/interstitial cystitis, focusing on translational relevance. The authors discussed mechanistic links to symptoms and emerging interventions. Integration into clinical practice is also discussed, highlighting crucial gaps in causality, biomarkers and therapeutic targeting.
Read more >>
JUL
21
Mohs micrographic surgery and reconstruction for glans and urethral squamous cell carcinoma
By:
Grant Sprow
on
JUL
21
Nature Reviews Urology, Published online: 21 July 2026; doi:10.1038/s41585-026-01176-1Mohs micrographic surgery offers a tissue-sparing alternative to penectomy for penile squamous cell carcinoma involving the glans and distal urethra, yet technical guidance remains scarce. We detail the surgical approach, specimen handling and reconstruction strategies to help surgeons navigate this challenging procedure and improve patient access to organ-preserving care.
Read more >>
JUL
20
Extending a pleasure-based paradigm: reflections on male-centred assumptions in sexual medicine
By:
Sam Geuens
on
JUL
20
Nature Reviews Urology, Published online: 20 July 2026; doi:10.1038/s41585-026-01175-2Extending a pleasure-based paradigm: reflections on male-centred assumptions in sexual medicine
Read more >>
JUL
20
Escaping the matrix: disrupted integrin signalling enables neuroendocrine differentiation
By:
Jacob Egelberg
on
JUL
20
Nature Reviews Urology, Published online: 20 July 2026; doi:10.1038/s41585-026-01177-0Escaping the matrix: disrupted integrin signalling enables neuroendocrine differentiation
Read more >>
JUL
09
Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer
By:
Sean A. Fletcher
on
JUL
09
Nature Reviews Urology, Published online: 09 July 2026; doi:10.1038/s41585-026-01172-5This Review provides an overview of currently available intraprostatic immunotherapy approaches, discussing rationale, main strategies, results from early-phase trials and the current limitations associated with this approach. The authors also discuss future perspectives regarding clinical implementation, describing opportunities and challenges.
Read more >>
JUL
01
Untangling the anterolateral periprostatic neurovasculature and its implications for nerve-sparing radical prostatectomy
By:
Behnam Nabavizadeh
on
JUL
01
Nature Reviews Urology, Published online: 01 July 2026; doi:10.1038/s41585-026-01169-0Several studies have demonstrated that a posterior approach to nerve sparing by preserving more anterolateral periprostatic tissue can improve erectile function by more than twofold. Review of the evidence regarding periprostatic nerve distribution suggests a potential underappreciation of the distribution and functional relevance of nerve fibres along the anterior prostate.
Read more >>
JUN
26
The role of CFTR in spermatogenesis and sperm quality
By:
Sara C. Pereira
on
JUN
26
Nature Reviews Urology, Published online: 26 June 2026; doi:10.1038/s41585-026-01173-4Cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, which has long been associated with systemic disease, also has under-recognized roles in male fertility. This Review outlines its contributions to spermatogenesis, sperm function and ion homeostasis, and links reduced expression to impaired sperm quality, highlighting emerging therapeutic strategies that might improve reproductive outcomes in individuals with CFTR deficiency.
Read more >>
JUN
22
Urolithiasis in patients with cancer
By:
Priya Dave
on
JUN
22
Nature Reviews Urology, Published online: 22 June 2026; doi:10.1038/s41585-026-01168-1In this Review, the authors explore the risk factors for urolithiasis in patients with cancer, the associations between urolithiasis and urinary tract cancers, the pathogenesis of urolithiasis in patients with urinary tract cancer and special considerations for management of urolithiasis after urinary tract diversion for cancer.
Read more >>
Weitere Beiträge
Share
Tweet
Share
Mail
English version of this site is mostly translated automatically using "google translate". In case of language difficulties please do not hesitate to contact me.
Share by: